Theravance Announces FDA Approval of VIBATIV(R) (telavancin) for the …

Monitor renal function in all patients receiving VIBATIV(R) prior to initiation of treatment, during treatment, and at the end of therapy. If renal function decreases, the benefit of continuing VIBATIV(R) versus discontinuing and initiating therapy …
See all stories on this topic »